1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. Italy >
  5. Quince Therapeutics Acquires EryDel

M&A Deal Summary

Quince Therapeutics Acquires EryDel

On July 24, 2023, Quince Therapeutics acquired life science company EryDel

Acquisition Highlights
  • This is Quince Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Quince Therapeutics’ 1st transaction in Italy.

M&A Deal Summary
Date 2023-07-24
Target EryDel
Sector Life Science
Buyer(s) Quince Therapeutics
Deal Type Add-on Acquisition
Advisor(s) Perella Weinberg Partners (Financial)
Goodwin Procter
Clifford Chance (Legal)

Target

EryDel

Modena, Italy
EryDel is late-stage biotech company aimed at developing and commercializing therapies for the treatment of rare diseases delivered by its proprietary red blood cell technology. EryDel is based in Modena, Italy.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Quince Therapeutics

South San Francisco, California, United States
Category Company
Founded 2012
Sector Life Science
Employees36
Revenue 27M USD (2023)
DESCRIPTION

Quince Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with rare and degenerative diseases. Quince Therapeutics was founded in 2012 and is based in South San Francisco, California.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
Country: Italy M&A 1 of 1
Year: 2023 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-05-10 Novosteo

West Lafayette, Indiana, United States

Novosteo is a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer, and injury. Novosteo was founded in 2017 and is based in West Lafayette, Indiana.

Buy -
Mergr

Solution for

Product

Company

Legal